COMMUNIQUÉS West-GlobeNewswire

Stipple Bio Appoints Biopharma Business Development Leader Roland Gendron as Chief Business Officer
07/07/2026
– Seasoned executive brings extensive leadership experience spanning corporate development, business development and pipeline strategy – – Track record includes helping build and advance leading oncology franchises at [...]
Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes
07/07/2026
MIAMI, July 07, 2026 (GLOBE NEWSWIRE) -- Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical [...]
Carbonium Core CEO Details Strategy to Supply Critical Material Powering the AI-Driven Nuclear Renaissance
07/07/2026
Management outlines commercialization roadmap toward a potential $1.5 billion annual revenue opportunity as the Company seeks to build America's first commercial-scale domestic supply chain for nuclear-grade graphite [...]
Arnatar Therapeutics Receives China NMPA Clearance to Initiate First-in-Human Study of ART5, a First-in-Class Up-Regulating ASO Designed to Restore Polycystin-1 for the Treatment of ADPKD
07/07/2026
ART5 is designed to address the most common root cause of ADPKD by targeting PKD1, potentially restoring PC1 production in approximately 85% of patients First-in-human SAD study in healthy volunteers expected to [...]
AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program
07/07/2026
CEO Thomas Equels discusses recent clinical progress, upcoming milestones and the Company's commitment to advancing Ampligen® for patients with pancreatic cancer Access it here OCALA, Fla., July 07, 2026 (GLOBE NEWSWIRE [...]
Alamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer’s Disease Research
07/07/2026
eMTBR-Tau offers a non-invasive, blood-based measurement of the tau tangle burden, the core pathology associated with disease progression and cognitive decline in Alzheimer’s disease Immunoassay for eMTBR-Tau is [...]
Oncotelic Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion Underway
07/07/2026
Clinical Program Advances Following Favorable Safety Review; Peer-Reviewed Publication Further Validates Deciparticle ™ Platform SAN DIEGO, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Oncotelic (OTCQB:OTLC), an AI/Robotic [...]
A $190 Billion Weight-Loss Boom Has Exposed a Tissue-Restoration Gap Today’s Injectables Were Not Built to Fill
07/07/2026
Conexeu Completes 12-Month Preclinical P.R.O.O.F Study, Supporting Its Intended Move Into the $11 Billion Medical Aesthetics Market as a Platform¹ Study Highlights P.R.O.O.F study complete, marking an important catalyst [...]
Nu-Tek BioSciences Present Cell Nutrient Innovation, Raw Material Expertise at SIMB 2026
07/07/2026
Nu-Tek will present data showing how its animal-free culture media nutrients improve yield, enhance processes, and strengthen supply security for bioprocessing. MINNETONKA, Minn., July 07, 2026 (GLOBE NEWSWIRE) -- Nu- [...]
New Clinical Study Data, Featuring Nanox.AI Cardiac Solution to Be Presented at SCCT 2026
07/07/2026
New SCCT abstracts from Brigham and Women’s Hospital highlight the performance and clinical utility of Nanox.AI’s FDA-cleared cardiac AI solution, showing high agreement with expert assessment and its potential role in [...]
Silo Pharma Subsidiary QwikAgents Set to Advance Enterprise AI Agent Platform through NVIDIA Developer Program
07/07/2026
NVIDIA developer program resources expected to support autonomous AI agent innovation and marketing SARASOTA, FLA., July 07, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a diversified [...]
SPRINT® PNS Publication Highlights Sustained Benefits in Low Back Pain Patients
07/07/2026
CLEVELAND, July 07, 2026 (GLOBE NEWSWIRE) -- SPR announced the publication of long-term data in the journal Pain and Therapy from a cross-sectional follow-up survey of real-world patients (n=602) with chronic low back [...]
Press Release Biocartis NV: Biocartis and Discovery Life Sciences Announce Strategic Collaboration to Advance Precision Oncology Diagnostics
07/07/2026
PRESS RELEASE, July 07, 2026 – 08:00 CDT Biocartis and Discovery Life Sciences Announce Strategic Collaboration to Advance Precision Oncology Diagnostics ITASCA, IL, US and HUNTSVILLE, AL, US – July 07, 2026. Today, [...]
Clinical Excellence in Continuity of Care: Counterpart Assistant (CA) Use Associated With Stronger Performance Across Transitions of Care Measures and Post-Hospitalization Follow-Up
07/07/2026
CA-enabled PCPs showed better HEDIS® post-acute performance, including 33% higher discharge information receipt and an 11% higher rate of post-discharge medication reconciliation, underscoring the role of AI-enabled [...]
ImageneBio Appoints Matt Robbins as General Counsel
07/07/2026
Brings more than 15 years of corporate, securities, and transactional experience advising public and private life sciences companies SAN DIEGO, July 07, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA, “Imagene” [...]
Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum
07/07/2026
WAYNE, Pa., July 07, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated [...]
Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader
07/07/2026
Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera’s KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end 2026 and late 2027, [...]
ITM Announces Primary Results from the Phase 3 COMPETE Trial Published in The Lancet Comparing ¹⁷⁷Lu-edotreotide (ITM-11) vs. Everolimus in Advanced GEP-NETs
07/07/2026
Investigational n.c.a. 177 Lu-edotreotide (ITM-11) demonstrated a significantly higher progression-free survival and objective response rate vs. everolimus Garching / Munich, July 7, 2026 – ITM Isotope Technologies [...]
Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP
07/07/2026
PALO ALTO, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Semnur Pharmaceuticals, Inc. (“Semnur” or the “Company”) (OTC: SMNR) , a clinical late-stage specialty pharmaceutical company focused on the development and [...]

Pages